{"id":77195,"date":"2026-11-18T18:15:35","date_gmt":"2026-11-18T18:15:35","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?page_id=77195"},"modified":"2026-11-19T05:55:55","modified_gmt":"2026-11-19T05:55:55","slug":"daily-analyst-ratings","status":"publish","type":"page","link":"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/","title":{"rendered":"Daily Analyst Ratings"},"content":{"rendered":"<nav aria-label=\"Analyst research tools\" style=\"display:flex;flex-wrap:wrap;gap:12px;margin:0 0 28px;padding:20px 24px;background:#f3f7fb;border:1px solid #d9e3ed;border-radius:10px;align-items:center;\"><span style=\"font-weight:700;color:#173b60;margin-right:8px;\">Explore our research tools<\/span><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/analyst-target-tool\/\" style=\"display:inline-block;padding:12px 20px;border-radius:6px;background:#173b60;color:#ffffff;text-decoration:none;font-weight:700;line-height:1.4;\">Target Tool &rarr;<\/a><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/analyst-ranking-tool\/\" style=\"display:inline-block;padding:12px 20px;border-radius:6px;background:#ffffff;color:#173b60;border:1px solid #173b60;text-decoration:none;font-weight:700;line-height:1.4;\">Analyst Ranking Tool &rarr;<\/a><\/nav>\n<div id=\"sta-daily-ratings\">\n<style>\n#sta-daily-ratings{font:14px\/1.6 system-ui,sans-serif;color:#183149}#sta-daily-ratings *{box-sizing:border-box}#sta-daily-ratings .dr-hero{background:#102b46;color:#fff;padding:30px;border-left:4px solid #70975b;margin-bottom:24px}#sta-daily-ratings .dr-hero h2{font:700 32px\/1.15 Georgia,serif;color:#fff;margin:8px 0 12px}#sta-daily-ratings .dr-eyebrow{font-size:11px;letter-spacing:.13em;color:#b6d6a6;font-weight:750;text-transform:uppercase}#sta-daily-ratings .dr-hero p{color:#dae5ef;margin:0}#sta-daily-ratings .dr-stats{display:grid;grid-template-columns:repeat(3,1fr);gap:15px;margin:22px 0}#sta-daily-ratings .dr-stat{padding:18px;background:#f1f5f8;border-top:3px solid #70975b}#sta-daily-ratings .dr-stat strong{display:block;font:700 29px Georgia,serif}#sta-daily-ratings .dr-controls{display:flex;gap:14px;align-items:end;flex-wrap:wrap;background:#edf3eb;padding:18px;margin-bottom:18px}#sta-daily-ratings label{display:flex;flex-direction:column;gap:5px;font-size:12px;font-weight:700}#sta-daily-ratings input,#sta-daily-ratings select{background:#fff;color:#183149;border:1px solid #bdcbd6;padding:10px;border-radius:3px;min-height:43px;font:14px system-ui,sans-serif;max-width:100%}#sta-daily-ratings button{background:#183d62;color:#fff;border:0;border-radius:3px;padding:11px 17px;cursor:pointer;font:700 13px system-ui,sans-serif}#sta-daily-ratings .dr-search{flex:1;min-width:200px}#sta-daily-ratings .dr-links{display:flex;gap:18px;flex-wrap:wrap;margin-bottom:18px}#sta-daily-ratings a{color:#1764ad;font-weight:650}#sta-daily-ratings .dr-wrap{overflow:auto;border:1px solid #d5dfe6}#sta-daily-ratings table{border-collapse:collapse;width:100%;min-width:1000px;margin:0;font-size:12px}#sta-daily-ratings th{text-align:left;background:#102b46;color:#fff;white-space:nowrap;padding:13px 12px}#sta-daily-ratings td{padding:13px 12px;border-bottom:1px solid #dce5ee;vertical-align:top}#sta-daily-ratings tr:nth-child(even){background:#f5f8fa}#sta-daily-ratings td strong{font-size:13px}#sta-daily-ratings td small{display:block;color:#637184;font-size:10px}#sta-daily-ratings .dr-badge{background:#eaf0f5;color:#183d62;padding:4px 7px;display:inline-block;font-size:11px;font-weight:700;white-space:nowrap}#sta-daily-ratings .dr-up{background:#e7f1e4;color:#306238}#sta-daily-ratings .dr-down{background:#f9e9e9;color:#953d42}#sta-daily-ratings .dr-note{font-size:12px;color:#637184;margin:15px 0}#sta-daily-ratings .dr-sources{margin-top:24px;border-top:1px solid #d5dfe6;padding-top:18px}#sta-daily-ratings details{max-width:190px}#sta-daily-ratings summary{cursor:pointer;color:#1764ad}#sta-daily-ratings [hidden]{display:none!important}@media(max-width:600px){#sta-daily-ratings .dr-hero{padding:23px}#sta-daily-ratings .dr-hero h2{font-size:27px}#sta-daily-ratings .dr-stat{padding:12px}#sta-daily-ratings .dr-stat strong{font-size:24px}#sta-daily-ratings .dr-controls label{flex:1;min-width:130px}}\n<\/style>\n<header class=\"dr-hero\"><span class=\"dr-eyebrow\">STA Research \u00b7 Analyst intelligence<\/span><h2>Daily analyst calls. One clear view.<\/h2><p>Search published Canadian and U.S. analyst updates by company, firm and action.<\/p><\/header>\n<div class=\"dr-links\"><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/?ratings_date=2026-11-19\">Today<\/a><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/\">Latest available day<\/a><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/analyst-ratings-updates\/\">Report archive &rarr;<\/a><\/div>\n<h3>November 18, 2026<\/h3>\n<div class=\"dr-stats\"><div class=\"dr-stat\"><strong>283<\/strong>Published calls<\/div><div class=\"dr-stat\"><strong>14<\/strong>Upgrades<\/div><div class=\"dr-stat\"><strong>16<\/strong>Downgrades<\/div><\/div>\n<p class=\"dr-note\">Canada: 24 calls &nbsp; U.S.: 259 calls &nbsp; <\/p>\n<form method=\"get\" class=\"dr-controls\"><label>Report date<select name=\"ratings_date\" id=\"dr-date\"><option value=\"2026-11-18\"  selected='selected'>Nov 18, 2026<\/option><option value=\"2026-11-17\" >Nov 17, 2026<\/option><option value=\"2026-11-16\" >Nov 16, 2026<\/option><option value=\"2026-11-13\" >Nov 13, 2026<\/option><option value=\"2026-11-12\" >Nov 12, 2026<\/option><option value=\"2026-11-11\" >Nov 11, 2026<\/option><option value=\"2026-11-10\" >Nov 10, 2026<\/option><option value=\"2026-11-09\" >Nov 9, 2026<\/option><option value=\"2026-11-06\" >Nov 6, 2026<\/option><option value=\"2026-11-05\" >Nov 5, 2026<\/option><option value=\"2026-11-04\" >Nov 4, 2026<\/option><option value=\"2026-11-03\" >Nov 3, 2026<\/option><option value=\"2026-11-02\" >Nov 2, 2026<\/option><option value=\"2026-10-30\" >Oct 30, 2026<\/option><option value=\"2026-10-29\" >Oct 29, 2026<\/option><option value=\"2026-10-28\" >Oct 28, 2026<\/option><option value=\"2026-10-27\" >Oct 27, 2026<\/option><option value=\"2026-10-26\" >Oct 26, 2026<\/option><option value=\"2026-10-22\" >Oct 22, 2026<\/option><option value=\"2026-10-21\" >Oct 21, 2026<\/option><option value=\"2026-10-20\" >Oct 20, 2026<\/option><option value=\"2026-10-19\" >Oct 19, 2026<\/option><option value=\"2026-10-16\" >Oct 16, 2026<\/option><option value=\"2026-10-15\" >Oct 15, 2026<\/option><option value=\"2026-10-14\" >Oct 14, 2026<\/option><option value=\"2026-10-13\" >Oct 13, 2026<\/option><option value=\"2026-10-12\" >Oct 12, 2026<\/option><option value=\"2026-10-08\" >Oct 8, 2026<\/option><option value=\"2026-10-07\" >Oct 7, 2026<\/option><option value=\"2026-10-06\" >Oct 6, 2026<\/option><option value=\"2026-10-05\" >Oct 5, 2026<\/option><option value=\"2026-10-02\" >Oct 2, 2026<\/option><option value=\"2026-10-01\" >Oct 1, 2026<\/option><option value=\"2026-09-30\" >Sep 30, 2026<\/option><option value=\"2026-09-22\" >Sep 22, 2026<\/option><option value=\"2026-09-21\" >Sep 21, 2026<\/option><option value=\"2026-09-18\" >Sep 18, 2026<\/option><option value=\"2026-09-17\" >Sep 17, 2026<\/option><option value=\"2026-09-16\" >Sep 16, 2026<\/option><option value=\"2026-09-15\" >Sep 15, 2026<\/option><option value=\"2026-09-14\" >Sep 14, 2026<\/option><option value=\"2026-09-11\" >Sep 11, 2026<\/option><option value=\"2026-09-10\" >Sep 10, 2026<\/option><option value=\"2026-09-09\" >Sep 9, 2026<\/option><option value=\"2026-09-08\" >Sep 8, 2026<\/option><option value=\"2026-09-04\" >Sep 4, 2026<\/option><option value=\"2026-09-03\" >Sep 3, 2026<\/option><option value=\"2026-09-02\" >Sep 2, 2026<\/option><option value=\"2026-09-01\" >Sep 1, 2026<\/option><option value=\"2026-08-31\" >Aug 31, 2026<\/option><option value=\"2026-08-28\" >Aug 28, 2026<\/option><option value=\"2026-08-27\" >Aug 27, 2026<\/option><option value=\"2026-08-26\" >Aug 26, 2026<\/option><option value=\"2026-08-25\" >Aug 25, 2026<\/option><option value=\"2026-08-24\" >Aug 24, 2026<\/option><option value=\"2026-08-21\" >Aug 21, 2026<\/option><option value=\"2026-08-20\" >Aug 20, 2026<\/option><option value=\"2026-08-19\" >Aug 19, 2026<\/option><option value=\"2026-08-18\" >Aug 18, 2026<\/option><option value=\"2026-08-17\" >Aug 17, 2026<\/option><option value=\"2026-08-14\" >Aug 14, 2026<\/option><option value=\"2026-08-13\" >Aug 13, 2026<\/option><option value=\"2026-08-12\" >Aug 12, 2026<\/option><option value=\"2026-08-11\" >Aug 11, 2026<\/option><option value=\"2026-08-10\" >Aug 10, 2026<\/option><option value=\"2026-08-07\" >Aug 7, 2026<\/option><option value=\"2026-08-06\" >Aug 6, 2026<\/option><option value=\"2026-08-05\" >Aug 5, 2026<\/option><option value=\"2026-07-31\" >Jul 31, 2026<\/option><option value=\"2026-07-30\" >Jul 30, 2026<\/option><option value=\"2026-07-29\" >Jul 29, 2026<\/option><option value=\"2026-07-28\" >Jul 28, 2026<\/option><option value=\"2026-07-23\" >Jul 23, 2026<\/option><option value=\"2026-07-22\" >Jul 22, 2026<\/option><option value=\"2026-07-21\" >Jul 21, 2026<\/option><option value=\"2026-07-20\" >Jul 20, 2026<\/option><option value=\"2026-07-17\" >Jul 17, 2026<\/option><option value=\"2026-07-16\" >Jul 16, 2026<\/option><option value=\"2026-07-15\" >Jul 15, 2026<\/option><option value=\"2026-07-14\" >Jul 14, 2026<\/option><option value=\"2026-07-13\" >Jul 13, 2026<\/option><option value=\"2026-07-10\" >Jul 10, 2026<\/option><option value=\"2026-07-09\" >Jul 9, 2026<\/option><option value=\"2026-07-08\" >Jul 8, 2026<\/option><option value=\"2026-07-07\" >Jul 7, 2026<\/option><option value=\"2026-07-06\" >Jul 6, 2026<\/option><option value=\"2026-07-03\" >Jul 3, 2026<\/option><option value=\"2026-07-02\" >Jul 2, 2026<\/option><option value=\"2026-07-01\" >Jul 1, 2026<\/option><option value=\"2026-06-30\" >Jun 30, 2026<\/option><option value=\"2026-06-29\" >Jun 29, 2026<\/option><option value=\"2026-06-26\" >Jun 26, 2026<\/option><option value=\"2026-06-25\" >Jun 25, 2026<\/option><option value=\"2026-06-24\" >Jun 24, 2026<\/option><option value=\"2026-06-23\" >Jun 23, 2026<\/option><option value=\"2026-06-22\" >Jun 22, 2026<\/option><option value=\"2026-06-19\" >Jun 19, 2026<\/option><option value=\"2026-06-18\" >Jun 18, 2026<\/option><\/select><\/label><button type=\"submit\">Load date<\/button><label class=\"dr-search\">Company, ticker or analyst<input id=\"dr-search\" type=\"search\" placeholder=\"Search company, ticker or firm\" \/><\/label><label>Market<select id=\"dr-market\"><option value=\"\">All markets<\/option><option>Canada<\/option><option>U.S.<\/option><\/select><\/label><label>Action<select id=\"dr-action\"><option value=\"\">All actions<\/option><option>Upgrade<\/option><option>Downgrade<\/option><option>Target Up<\/option><option>Target Down<\/option><option>Maintains<\/option><option>Initiates<\/option><option>Resumes<\/option><\/select><\/label><\/form>\n<p id=\"dr-count\" role=\"status\" aria-live=\"polite\">283 calls shown<\/p>\n<div class=\"dr-wrap\" tabindex=\"0\" role=\"region\" aria-label=\"Daily analyst ratings table\"><table><thead><tr><th scope=\"col\">Company \/ Ticker<\/th><th scope=\"col\">Market<\/th><th scope=\"col\">Analyst firm<\/th><th scope=\"col\">Action<\/th><th scope=\"col\">Previous rating<\/th><th scope=\"col\">Rating<\/th><th scope=\"col\">Previous target<\/th><th scope=\"col\">New target<\/th><th scope=\"col\">Source<\/th><\/tr><\/thead><tbody>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>AbbVie<\/strong><small>ABBV<\/small><\/td><td>U.S.<\/td><td>Piper Sandler<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>\u2014<\/td><td>US$349.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>AbbVie (ABBV) \u2014 Piper Sandler reiterated its Overweight rating with a price target of $349.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>AbCellera Biologics<\/strong><small>ABCL<\/small><\/td><td>U.S.<\/td><td>Lake Street Capital<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$19.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>AbCellera Biologics (ABCL) \u2014 Lake Street Capital initiated coverage with a Buy rating and a price target of $19.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>ACADIA Pharmaceuticals<\/strong><small>ACAD<\/small><\/td><td>U.S.<\/td><td>Oppenheimer<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Market Perform<\/td><td>US$23.00<\/td><td>US$21.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>ACADIA Pharmaceuticals (ACAD) \u2014 Oppenheimer lowered its price target from $23.00 to $21.00, maintaining a Market Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Adeia<\/strong><small>ADEA<\/small><\/td><td>U.S.<\/td><td>Rosenblatt Securities<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$35.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Adeia (ADEA) \u2014 Rosenblatt Securities reiterated its Buy rating with a price target of $35.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Adherex Technologies<\/strong><small>FENC<\/small><\/td><td>U.S.<\/td><td>HC Wainwright<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$16.00<\/td><td>US$17.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Adherex Technologies (FENC) \u2014 HC Wainwright raised its price target from $16.00 to $17.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>AECOM<\/strong><small>ACM<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$73.00<\/td><td>US$90.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>AECOM (ACM) \u2014 Barclays raised its price target from $73.00 to $90.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>AECOM<\/strong><small>ACM<\/small><\/td><td>U.S.<\/td><td>KeyCorp<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$78.00<\/td><td>US$97.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>AECOM (ACM) \u2014 KeyCorp raised its price target from $78.00 to $97.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Affiliated Managers Group<\/strong><small>AMG<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$583.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Affiliated Managers Group (AMG) \u2014 TD Cowen reiterated its Buy rating with a price target of $583.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Aldebaran Resources Inc.<\/strong><small>ALDE:CA<\/small><\/td><td>Canada<\/td><td>National Bank<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>C$5.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Aldebaran Resources Inc. (ALDE:CA) \u2014 National Bank maintained an Outperform rating with a price target of C$5.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Alnylam Pharmaceuticals<\/strong><small>ALNY<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$254.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Alnylam Pharmaceuticals (ALNY) \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $254.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>Alnylam Pharmaceuticals<\/strong><small>ALNY<\/small><\/td><td>U.S.<\/td><td>Rodman &amp; Renshaw<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Alnylam Pharmaceuticals (ALNY) \u2014 Rodman &amp; Renshaw downgraded the stock to Neutral.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Amer Sports<\/strong><small>AS<\/small><\/td><td>U.S.<\/td><td>Cantor Fitzgerald<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$46.00<\/td><td>US$47.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Amer Sports (AS) \u2014 Cantor Fitzgerald raised its price target from $46.00 to $47.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Amer Sports<\/strong><small>AS<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$62.00<\/td><td>US$56.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Amer Sports (AS) \u2014 UBS Group lowered its price target from $62.00 to $56.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>American Axle &amp; Manufacturing<\/strong><small>DCH<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$7.00<\/td><td>US$6.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>American Axle &amp; Manufacturing (DCH) \u2014 Morgan Stanley lowered its price target from $7.00 to $6.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>American Axle &amp; Manufacturing<\/strong><small>DCH<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$10.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>American Axle &amp; Manufacturing (DCH) \u2014 TD Cowen reiterated its Buy rating with a price target of $10.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Antero Resources<\/strong><small>AR<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$51.00<\/td><td>US$52.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Antero Resources (AR) \u2014 Morgan Stanley raised its price target from $51.00 to $52.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>APA Corporation<\/strong><small>APA<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Underweight<\/td><td>US$43.00<\/td><td>US$44.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>APA Corporation (APA) \u2014 Morgan Stanley raised its price target from $43.00 to $44.00, maintaining an Underweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>AppLovin<\/strong><small>APP<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$400.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>AppLovin (APP) \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $400.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Atrium Mortgage Investment Corporation<\/strong><small>AI:CA<\/small><\/td><td>Canada<\/td><td>Fundamental Research<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>C$12.49<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Atrium Mortgage Investment Corporation (AI:CA) \u2014 Fundamental Research maintained a Buy rating with a price target of C$12.49.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Baidu<\/strong><small>BIDU<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$80.00<\/td><td>US$72.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Baidu (BIDU) \u2014 Barclays lowered its price target from $80.00 to $72.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Baidu<\/strong><small>BIDU<\/small><\/td><td>U.S.<\/td><td>Stifel Nicolaus<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$83.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Baidu (BIDU) \u2014 Stifel Nicolaus reiterated its price target with a price target of $83.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Baidu<\/strong><small>BIDU<\/small><\/td><td>U.S.<\/td><td>Susquehanna<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$105.00<\/td><td>US$75.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Baidu (BIDU) \u2014 Susquehanna lowered its price target from $105.00 to $75.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Bally&#039;s<\/strong><small>BALY<\/small><\/td><td>U.S.<\/td><td>Truist Financial<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Hold<\/td><td>US$10.00<\/td><td>US$9.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Bally&#039;s (BALY) \u2014 Truist Financial lowered its price target from $10.00 to $9.00, maintaining a Hold rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>BILL Holdings, Inc.<\/strong><small>BILL<\/small><\/td><td>U.S.<\/td><td>BMO Capital Markets<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Market Perform<\/td><td>US$56.00<\/td><td>US$68.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>BILL Holdings, Inc. (BILL) \u2014 BMO Capital Markets raised its price target from $56.00 to $68.00, maintaining a Market Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Biogen<\/strong><small>BIIB<\/small><\/td><td>U.S.<\/td><td>Needham &amp; Company LLC<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Biogen (BIIB) \u2014 Needham &amp; Company LLC reiterated its Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Bitdeer Technologies Group<\/strong><small>BTDR<\/small><\/td><td>U.S.<\/td><td>StoneX<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$22.00<\/td><td>US$15.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Bitdeer Technologies Group (BTDR) \u2014 StoneX lowered its price target from $22.00 to $15.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Black Diamond Group Ltd.<\/strong><small>BDI:CA<\/small><\/td><td>Canada<\/td><td>Canaccord Genuity<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>C$26.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Black Diamond Group Ltd. (BDI:CA) \u2014 Canaccord Genuity maintained a Buy rating with a price target of C$26.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>BlackLine<\/strong><small>BL<\/small><\/td><td>U.S.<\/td><td>BMO Capital Markets<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Market Perform<\/td><td>US$32.00<\/td><td>US$30.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>BlackLine (BL) \u2014 BMO Capital Markets lowered its price target from $32.00 to $30.00, maintaining a Market Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>Bridger Aerospace Group<\/strong><small>BAER<\/small><\/td><td>U.S.<\/td><td>Canaccord Genuity Group<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Hold<\/td><td>\u2014<\/td><td>US$1.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Bridger Aerospace Group (BAER) \u2014 Canaccord Genuity Group downgraded the stock from Buy to Hold, with a price target of $1.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>Bridger Aerospace Group<\/strong><small>BAER<\/small><\/td><td>U.S.<\/td><td>Stifel Nicolaus<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Hold<\/td><td>\u2014<\/td><td>US$0.25<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Bridger Aerospace Group (BAER) \u2014 Stifel Nicolaus downgraded the stock from Buy to Hold, with a price target of $0.25.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>BrightSpring Health Services<\/strong><small>BTSG<\/small><\/td><td>U.S.<\/td><td>BMO Capital Markets<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$80.00<\/td><td>US$84.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>BrightSpring Health Services (BTSG) \u2014 BMO Capital Markets raised its price target from $80.00 to $84.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Brookfield<\/strong><small>BN<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$54.00<\/td><td>US$52.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Brookfield (BN) \u2014 Morgan Stanley lowered its price target from $54.00 to $52.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Brookfield Asset Management<\/strong><small>BAM<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$54.00<\/td><td>US$57.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Brookfield Asset Management (BAM) \u2014 Morgan Stanley raised its price target from $54.00 to $57.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Builders FirstSource<\/strong><small>BLDR<\/small><\/td><td>U.S.<\/td><td>Royal Bank Of Canada<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Sector Perform<\/td><td>\u2014<\/td><td>US$56.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Builders FirstSource (BLDR) \u2014 Royal Bank Of Canada reiterated its Sector Perform rating with a price target of $56.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>BWX Technologies<\/strong><small>BWXT<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$230.00<\/td><td>US$180.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>BWX Technologies (BWXT) \u2014 TD Cowen lowered its price target from $230.00 to $180.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Calumet<\/strong><small>CLMT<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Hold<\/td><td>US$40.00<\/td><td>US$37.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Calumet (CLMT) \u2014 TD Cowen lowered its price target from $40.00 to $37.00, maintaining a Hold rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>Camtek<\/strong><small>CAMT<\/small><\/td><td>U.S.<\/td><td>Northland Capital<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Market Perform<\/td><td>Outperform<\/td><td>\u2014<\/td><td>US$130.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Camtek (CAMT) \u2014 Northland Capital upgraded the stock from Market Perform to Outperform, with a price target of $130.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>Camtek<\/strong><small>CAMT<\/small><\/td><td>U.S.<\/td><td>Northland Securities<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Market Perform<\/td><td>Outperform<\/td><td>\u2014<\/td><td>US$130.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Camtek (CAMT) \u2014 Northland Securities upgraded the stock from Market Perform to Outperform, with a price target of $130.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Cardinal Health<\/strong><small>CAH<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$275.00<\/td><td>US$320.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Cardinal Health (CAH) \u2014 Barclays raised its price target from $275.00 to $320.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Caterpillar<\/strong><small>CAT<\/small><\/td><td>U.S.<\/td><td>DA Davidson<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$685.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Caterpillar (CAT) \u2014 DA Davidson reiterated its price target with a price target of $685.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Celsius<\/strong><small>CELH<\/small><\/td><td>U.S.<\/td><td>Wolfe Research<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>US$39.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Celsius (CELH) \u2014 Wolfe Research initiated coverage with a Outperform rating and a price target of $39.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Cencora<\/strong><small>COR<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$350.00<\/td><td>US$415.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Cencora (COR) \u2014 Barclays raised its price target from $350.00 to $415.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Ceva<\/strong><small>CEVA<\/small><\/td><td>U.S.<\/td><td>Rosenblatt Securities<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$49.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Ceva (CEVA) \u2014 Rosenblatt Securities reiterated its Buy rating with a price target of $49.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>CG Oncology<\/strong><small>CGON<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$102.00<\/td><td>US$117.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>CG Oncology (CGON) \u2014 Morgan Stanley raised its price target from $102.00 to $117.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>Charles Schwab<\/strong><small>SCHW<\/small><\/td><td>U.S.<\/td><td>Raymond James<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Outperform<\/td><td>Strong Buy<\/td><td>\u2014<\/td><td>US$135.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Charles Schwab (SCHW) \u2014 Raymond James upgraded the stock from Outperform to Strong Buy, with a price target of $135.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>Charles Schwab<\/strong><small>SCHW<\/small><\/td><td>U.S.<\/td><td>Raymond James Financial<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Outperform<\/td><td>Strong-Buy<\/td><td>\u2014<\/td><td>US$135.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Charles Schwab (SCHW) \u2014 Raymond James Financial upgraded the stock from Outperform to Strong-Buy, with a price target of $135.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Chemtrade Logistics Income Fund<\/strong><small>CHE.UN:CA<\/small><\/td><td>Canada<\/td><td>Scotiabank<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Sector Perform<\/td><td>\u2014<\/td><td>C$19.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Chemtrade Logistics Income Fund (CHE.UN:CA) \u2014 Scotiabank maintained a Sector Perform rating with a price target of C$19.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Chime Financial<\/strong><small>CHYM<\/small><\/td><td>U.S.<\/td><td>B. Riley Financial<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$45.00<\/td><td>US$55.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Chime Financial (CHYM) \u2014 B. Riley Financial reiterated its Buy rating with its price target from $45.00 to $55.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Chord Energy<\/strong><small>CHRD<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$178.00<\/td><td>US$183.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Chord Energy (CHRD) \u2014 Morgan Stanley raised its price target from $178.00 to $183.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Chord Energy<\/strong><small>CHRD<\/small><\/td><td>U.S.<\/td><td>Truist Financial<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$197.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Chord Energy (CHRD) \u2014 Truist Financial reiterated its price target with a price target of $197.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Church &amp; Dwight<\/strong><small>CHD<\/small><\/td><td>U.S.<\/td><td>Bank of America<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$115.00<\/td><td>US$125.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Church &amp; Dwight (CHD) \u2014 Bank of America raised its price target from $115.00 to $125.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Cleveland-Cliffs<\/strong><small>CLF<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$17.00<\/td><td>US$18.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Cleveland-Cliffs (CLF) \u2014 Wells Fargo &amp; Company raised its price target from $17.00 to $18.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Climb Bio<\/strong><small>CLYM<\/small><\/td><td>U.S.<\/td><td>Royal Bank Of Canada<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>US$23.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Climb Bio (CLYM) \u2014 Royal Bank Of Canada reiterated its Outperform rating with a price target of $23.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade|Target Up\"><td><strong>CNX Resources<\/strong><small>CNX<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Underweight<\/td><td>Equal Weight<\/td><td>US$34.00<\/td><td>US$36.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>CNX Resources (CNX) \u2014 Morgan Stanley upgraded the stock from Underweight to Equal Weight and changed its price target from $34.00 to $36.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Coca-Cola<\/strong><small>KO<\/small><\/td><td>U.S.<\/td><td>Wolfe Research<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Coca-Cola (KO) \u2014 Wolfe Research initiated coverage with a Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Commercial Metals<\/strong><small>CMC<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$70.00<\/td><td>US$63.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Commercial Metals (CMC) \u2014 Wells Fargo &amp; Company lowered its price target from $70.00 to $63.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>Comstock Resources<\/strong><small>CRK<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>\u2014<\/td><td>Underweight<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Comstock Resources (CRK) \u2014 Barclays downgraded the stock to Underweight.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>Comstock Resources<\/strong><small>CRK<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Equal Weight<\/td><td>Underweight<\/td><td>\u2014<\/td><td>US$13.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Comstock Resources (CRK) \u2014 Morgan Stanley downgraded the stock from Equal Weight to Underweight, with a price target of $13.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>ConocoPhillips<\/strong><small>COP<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$159.00<\/td><td>US$160.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>ConocoPhillips (COP) \u2014 Morgan Stanley raised its price target from $159.00 to $160.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Credicorp<\/strong><small>BAP<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$473.00<\/td><td>US$458.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Credicorp (BAP) \u2014 UBS Group lowered its price target from $473.00 to $458.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Crombie REIT<\/strong><small>CRR.UN:CA<\/small><\/td><td>Canada<\/td><td>CIBC<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>C$18.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Crombie REIT (CRR.UN:CA) \u2014 CIBC maintained an Outperform rating with a price target of C$18.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Resumes\"><td><strong>Crombie REIT<\/strong><small>CRR.UN:CA<\/small><\/td><td>Canada<\/td><td>TD Securities<\/td><td><span class=\"dr-badge \">Resumes<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>C$18.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Crombie REIT (CRR.UN:CA) \u2014 TD Securities resumed coverage with a Buy rating and a price target of C$18.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Cue Biopharma<\/strong><small>CUE<\/small><\/td><td>U.S.<\/td><td>B. Riley Financial<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Cue Biopharma (CUE) \u2014 B. Riley Financial reiterated its Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Deere &amp; Company<\/strong><small>DE<\/small><\/td><td>U.S.<\/td><td>Oppenheimer<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Deere &amp; Company (DE) \u2014 Oppenheimer reiterated its Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Devon Energy<\/strong><small>DVN<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$64.00<\/td><td>US$65.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Devon Energy (DVN) \u2014 Morgan Stanley raised its price target from $64.00 to $65.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Diamondback Energy<\/strong><small>FANG<\/small><\/td><td>U.S.<\/td><td>Royal Bank Of Canada<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>US$240.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Diamondback Energy (FANG) \u2014 Royal Bank Of Canada reiterated its Outperform rating with a price target of $240.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Disc Medicine<\/strong><small>IRON<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$92.00<\/td><td>US$104.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Disc Medicine (IRON) \u2014 Morgan Stanley raised its price target from $92.00 to $104.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>DLocal<\/strong><small>DLO<\/small><\/td><td>U.S.<\/td><td>Truist Financial<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$17.00<\/td><td>US$16.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>DLocal (DLO) \u2014 Truist Financial lowered its price target from $17.00 to $16.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Docusign<\/strong><small>DOCU<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$75.00<\/td><td>US$90.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Docusign (DOCU) \u2014 BTIG Research raised its price target from $75.00 to $90.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Target Up\"><td><strong>Dollarama Inc.<\/strong><small>DOL:CA<\/small><\/td><td>Canada<\/td><td>TD Securities<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>C$217.00<\/td><td>C$250.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Dollarama Inc. (DOL:CA) \u2014 TD Securities raised its price target from C$217.00 to C$250.00, maintaining a Buy rating and identifying Dollarama as one of its preferred investment ideas for 2027.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Duos Technologies Group<\/strong><small>DUOT<\/small><\/td><td>U.S.<\/td><td>Chardan Capital<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$9.50<\/td><td>US$5.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Duos Technologies Group (DUOT) \u2014 Chardan Capital lowered its price target from $9.50 to $5.50, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Dutch Bros<\/strong><small>BROS<\/small><\/td><td>U.S.<\/td><td>Guggenheim<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$76.00<\/td><td>US$62.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Dutch Bros (BROS) \u2014 Guggenheim lowered its price target from $76.00 to $62.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>Eaton<\/strong><small>ETN<\/small><\/td><td>U.S.<\/td><td>Erste Group Bank<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Hold<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Eaton (ETN) \u2014 Erste Group Bank downgraded the stock from Buy to Hold.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Ecolab<\/strong><small>ECL<\/small><\/td><td>U.S.<\/td><td>Oppenheimer<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$320.00<\/td><td>US$331.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Ecolab (ECL) \u2014 Oppenheimer raised its price target from $320.00 to $331.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Ecolab<\/strong><small>ECL<\/small><\/td><td>U.S.<\/td><td>Robert W. Baird<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$317.00<\/td><td>US$324.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Ecolab (ECL) \u2014 Robert W. Baird raised its price target from $317.00 to $324.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Ecolab<\/strong><small>ECL<\/small><\/td><td>U.S.<\/td><td>Stifel Nicolaus<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$337.00<\/td><td>US$356.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Ecolab (ECL) \u2014 Stifel Nicolaus raised its price target from $337.00 to $356.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Eikon Therapeutics<\/strong><small>EIKN<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>\u2014<\/td><td>US$30.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Eikon Therapeutics (EIKN) \u2014 Morgan Stanley lowered its price target to $30.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Elbit Systems<\/strong><small>ESLT<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$885.00<\/td><td>US$900.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Elbit Systems (ESLT) \u2014 JPMorgan Chase &amp; Co. raised its price target from $885.00 to $900.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>Elevance Health<\/strong><small>ELV<\/small><\/td><td>U.S.<\/td><td>Argus<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Hold<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$510.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Elevance Health (ELV) \u2014 Argus upgraded the stock from Hold to Buy, with a price target of $510.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Energizer<\/strong><small>ENR<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$22.00<\/td><td>US$25.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Energizer (ENR) \u2014 JPMorgan Chase &amp; Co. raised its price target from $22.00 to $25.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Energizer<\/strong><small>ENR<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$21.00<\/td><td>US$27.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Energizer (ENR) \u2014 Morgan Stanley raised its price target from $21.00 to $27.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Energizer<\/strong><small>ENR<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$22.00<\/td><td>US$28.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Energizer (ENR) \u2014 UBS Group raised its price target from $22.00 to $28.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade|Target Down\"><td><strong>Enovix<\/strong><small>ENVX<\/small><\/td><td>U.S.<\/td><td>Bank of America<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Neutral<\/td><td>Underperform<\/td><td>US$5.00<\/td><td>US$1.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Enovix (ENVX) \u2014 Bank of America downgraded the stock from Neutral to Underperform and changed its price target from $5.00 to $1.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Entrada Therapeutics<\/strong><small>TRDA<\/small><\/td><td>U.S.<\/td><td>Guggenheim<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$17.00<\/td><td>US$13.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Entrada Therapeutics (TRDA) \u2014 Guggenheim lowered its price target from $17.00 to $13.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>EOG Resources<\/strong><small>EOG<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$163.00<\/td><td>US$167.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>EOG Resources (EOG) \u2014 Morgan Stanley raised its price target from $163.00 to $167.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>EQT Corporation<\/strong><small>EQT<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$67.00<\/td><td>US$66.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>EQT Corporation (EQT) \u2014 Morgan Stanley lowered its price target from $67.00 to $66.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Expand Energy<\/strong><small>EXE<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$123.00<\/td><td>US$120.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Expand Energy (EXE) \u2014 Morgan Stanley lowered its price target from $123.00 to $120.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>ExxonMobil<\/strong><small>XOM<\/small><\/td><td>U.S.<\/td><td>Erste Group Bank<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Hold<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>ExxonMobil (XOM) \u2014 Erste Group Bank upgraded the stock from Hold to Buy.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Ferguson<\/strong><small>FERG<\/small><\/td><td>U.S.<\/td><td>Bank of America<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$315.00<\/td><td>US$320.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Ferguson (FERG) \u2014 Bank of America raised its price target from $315.00 to $320.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Franco-Nevada Corporation<\/strong><small>FNV:CA<\/small><\/td><td>Canada<\/td><td>CIBC<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>C$480.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Franco-Nevada Corporation (FNV:CA) \u2014 CIBC maintained an Outperform rating with a price target of C$480.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>Freeport-McMoRan<\/strong><small>FCX<\/small><\/td><td>U.S.<\/td><td>Erste Group Bank<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Hold<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Freeport-McMoRan (FCX) \u2014 Erste Group Bank downgraded the stock from Buy to Hold.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>fuboTV<\/strong><small>FUBO<\/small><\/td><td>U.S.<\/td><td>Barrington Research<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$16.00<\/td><td>US$12.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>fuboTV (FUBO) \u2014 Barrington Research lowered its price target from $16.00 to $12.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>fuboTV<\/strong><small>FUBO<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>fuboTV (FUBO) \u2014 BTIG Research reiterated its Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Futu<\/strong><small>FUTU<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$122.00<\/td><td>US$103.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Futu (FUTU) \u2014 JPMorgan Chase &amp; Co. lowered its price target from $122.00 to $103.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>GE HealthCare Technologies<\/strong><small>GEHC<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$83.00<\/td><td>US$91.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>GE HealthCare Technologies (GEHC) \u2014 BTIG Research raised its price target from $83.00 to $91.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>GE Vernova<\/strong><small>GEV<\/small><\/td><td>U.S.<\/td><td>Erste Group Bank<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Hold<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>GE Vernova (GEV) \u2014 Erste Group Bank downgraded the stock from Buy to Hold.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>GeneDx<\/strong><small>WGS<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$85.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>GeneDx (WGS) \u2014 BTIG Research reiterated its Buy rating with a price target of $85.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>General Fusion Group<\/strong><small>GFUZ<\/small><\/td><td>U.S.<\/td><td>Wedbush<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>\u2014<\/td><td>US$7.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>General Fusion Group (GFUZ) \u2014 Wedbush reiterated its Neutral rating with a price target of $7.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Generate Biomedicines<\/strong><small>GENB<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$22.00<\/td><td>US$21.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Generate Biomedicines (GENB) \u2014 Morgan Stanley lowered its price target from $22.00 to $21.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Geo Group<\/strong><small>GEO<\/small><\/td><td>U.S.<\/td><td>JonesTrading<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$42.75<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Geo Group (GEO) \u2014 JonesTrading reiterated its Buy rating with a price target of $42.75.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>GH Research<\/strong><small>GHRS<\/small><\/td><td>U.S.<\/td><td>Guggenheim<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$40.00<\/td><td>US$46.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>GH Research (GHRS) \u2014 Guggenheim raised its price target from $40.00 to $46.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Granite Point Mortgage Trust<\/strong><small>GPMT<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>\u2014<\/td><td>US$3.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Granite Point Mortgage Trust (GPMT) \u2014 UBS Group lowered its price target to $3.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Gray Media<\/strong><small>GTN<\/small><\/td><td>U.S.<\/td><td>Guggenheim<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$7.00<\/td><td>US$8.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Gray Media (GTN) \u2014 Guggenheim raised its price target from $7.00 to $8.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Greenwich LifeSciences<\/strong><small>GLSI<\/small><\/td><td>U.S.<\/td><td>HC Wainwright<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$69.00<\/td><td>US$70.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Greenwich LifeSciences (GLSI) \u2014 HC Wainwright raised its price target from $69.00 to $70.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Groupe Dynamite Inc.<\/strong><small>GRGD:CA<\/small><\/td><td>Canada<\/td><td>Scotiabank<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Sector Outperform<\/td><td>\u2014<\/td><td>C$75.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Groupe Dynamite Inc. (GRGD:CA) \u2014 Scotiabank maintained a Sector Outperform rating with a price target of C$75.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Guardant Health<\/strong><small>GH<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Guardant Health (GH) \u2014 TD Cowen reiterated its Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>HA Sustainable Infrastructure Capital<\/strong><small>HASI<\/small><\/td><td>U.S.<\/td><td>Jefferies Financial Group<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$46.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>HA Sustainable Infrastructure Capital (HASI) \u2014 Jefferies Financial Group reiterated its Buy rating with a price target of $46.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>HCA Healthcare<\/strong><small>HCA<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$425.00<\/td><td>US$475.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>HCA Healthcare (HCA) \u2014 JPMorgan Chase &amp; Co. raised its price target from $425.00 to $475.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Hershey<\/strong><small>HSY<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Hold<\/td><td>\u2014<\/td><td>US$173.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Hershey (HSY) \u2014 TD Cowen reiterated its Hold rating with a price target of $173.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Home Depot<\/strong><small>HD<\/small><\/td><td>U.S.<\/td><td>DA Davidson<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$377.00<\/td><td>US$390.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Home Depot (HD) \u2014 DA Davidson raised its price target from $377.00 to $390.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Home Depot<\/strong><small>HD<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$390.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Home Depot (HD) \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $390.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Home Depot<\/strong><small>HD<\/small><\/td><td>U.S.<\/td><td>Mizuho<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$390.00<\/td><td>US$385.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Home Depot (HD) \u2014 Mizuho lowered its price target from $390.00 to $385.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Home Depot<\/strong><small>HD<\/small><\/td><td>U.S.<\/td><td>Royal Bank Of Canada<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Sector Perform<\/td><td>US$342.00<\/td><td>US$334.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Home Depot (HD) \u2014 Royal Bank Of Canada lowered its price target from $342.00 to $334.00, maintaining a Sector Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Home Depot<\/strong><small>HD<\/small><\/td><td>U.S.<\/td><td>Sanford C. Bernstein<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Market Perform<\/td><td>US$357.00<\/td><td>US$360.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Home Depot (HD) \u2014 Sanford C. Bernstein raised its price target from $357.00 to $360.00, maintaining a Market Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Home Depot<\/strong><small>HD<\/small><\/td><td>U.S.<\/td><td>Truist Financial<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$373.00<\/td><td>US$376.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Home Depot (HD) \u2014 Truist Financial raised its price target from $373.00 to $376.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Home Depot<\/strong><small>HD<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$420.00<\/td><td>US$417.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Home Depot (HD) \u2014 UBS Group lowered its price target from $420.00 to $417.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>Hornbeck Offshore Services<\/strong><small>HOS<\/small><\/td><td>U.S.<\/td><td>Pickering Energy Partners<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Neutral<\/td><td>Outperform<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Hornbeck Offshore Services (HOS) \u2014 Pickering Energy Partners upgraded the stock from Neutral to Outperform.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Hyperfine<\/strong><small>HYPR<\/small><\/td><td>U.S.<\/td><td>B. Riley Financial<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$1.60<\/td><td>US$1.40<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Hyperfine (HYPR) \u2014 B. Riley Financial reiterated its Buy rating with its price target from $1.60 to $1.40.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Immix Biopharma<\/strong><small>IMMX<\/small><\/td><td>U.S.<\/td><td>Mizuho<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$23.00<\/td><td>US$22.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Immix Biopharma (IMMX) \u2014 Mizuho lowered its price target from $23.00 to $22.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Immix Biopharma<\/strong><small>IMMX<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$20.00<\/td><td>US$21.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Immix Biopharma (IMMX) \u2014 Morgan Stanley raised its price target from $20.00 to $21.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Immunic<\/strong><small>IMUX<\/small><\/td><td>U.S.<\/td><td>HC Wainwright<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Immunic (IMUX) \u2014 HC Wainwright reiterated its Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Target Up\"><td><strong>Imperial Oil Ltd.<\/strong><small>IMO:CA<\/small><\/td><td>Canada<\/td><td>BMO<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Underperform<\/td><td>C$133.00<\/td><td>C$138.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Imperial Oil Ltd. (IMO:CA) \u2014 BMO raised its price target from C$133.00 to C$138.00, maintaining an Underperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Innoviva<\/strong><small>INVA<\/small><\/td><td>U.S.<\/td><td>Piper Sandler<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>\u2014<\/td><td>US$29.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Innoviva (INVA) \u2014 Piper Sandler initiated coverage with a Overweight rating and a price target of $29.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade|Target Down\"><td><strong>Insulet<\/strong><small>PODD<\/small><\/td><td>U.S.<\/td><td>Stifel Nicolaus<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Hold<\/td><td>US$180.00<\/td><td>US$165.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Insulet (PODD) \u2014 Stifel Nicolaus downgraded the stock from Buy to Hold and changed its price target from $180.00 to $165.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Intuitive Surgical<\/strong><small>ISRG<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$454.00<\/td><td>US$513.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Intuitive Surgical (ISRG) \u2014 BTIG Research raised its price target from $454.00 to $513.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Ionis Pharmaceuticals<\/strong><small>IONS<\/small><\/td><td>U.S.<\/td><td>Guggenheim<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$80.00<\/td><td>US$65.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Ionis Pharmaceuticals (IONS) \u2014 Guggenheim lowered its price target from $80.00 to $65.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>ITT Inc.<\/strong><small>ITT<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$250.00<\/td><td>US$260.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>ITT Inc. (ITT) \u2014 TD Cowen raised its price target from $250.00 to $260.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>J. M. Smucker<\/strong><small>SJM<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$149.00<\/td><td>US$153.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>J. M. Smucker (SJM) \u2014 UBS Group raised its price target from $149.00 to $153.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Jamieson Wellness Inc.<\/strong><small>JWEL:CA<\/small><\/td><td>Canada<\/td><td>TD Securities<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Sell<\/td><td>\u2014<\/td><td>C$45.75<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Jamieson Wellness Inc. (JWEL:CA) \u2014 TD Securities maintained a Sell rating with a price target of C$45.75.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>JD.com<\/strong><small>JD<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$38.00<\/td><td>US$33.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>JD.com (JD) \u2014 Barclays lowered its price target from $38.00 to $33.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>JD.com<\/strong><small>JD<\/small><\/td><td>U.S.<\/td><td>Mizuho<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$37.00<\/td><td>US$34.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>JD.com (JD) \u2014 Mizuho lowered its price target from $37.00 to $34.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>JD.com<\/strong><small>JD<\/small><\/td><td>U.S.<\/td><td>Sanford C. Bernstein<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$40.00<\/td><td>US$38.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>JD.com (JD) \u2014 Sanford C. Bernstein lowered its price target from $40.00 to $38.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>JD.com<\/strong><small>JD<\/small><\/td><td>U.S.<\/td><td>StoneX<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$42.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>JD.com (JD) \u2014 StoneX reiterated its price target with a price target of $42.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Target Up\"><td><strong>Kelt Exploration Ltd.<\/strong><small>KEL:CA<\/small><\/td><td>Canada<\/td><td>Scotiabank<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Sector Outperform<\/td><td>C$13.50<\/td><td>C$14.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Kelt Exploration Ltd. (KEL:CA) \u2014 Scotiabank raised its price target from C$13.50 to C$14.00, maintaining a Sector Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Keurig Dr Pepper<\/strong><small>KDP<\/small><\/td><td>U.S.<\/td><td>Wolfe Research<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>US$42.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Keurig Dr Pepper (KDP) \u2014 Wolfe Research initiated coverage with a Outperform rating and a price target of $42.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Klarna Group<\/strong><small>KLAR<\/small><\/td><td>U.S.<\/td><td>Bank of America<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$19.00<\/td><td>US$20.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Klarna Group (KLAR) \u2014 Bank of America raised its price target from $19.00 to $20.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Klarna Group<\/strong><small>KLAR<\/small><\/td><td>U.S.<\/td><td>BMO Capital Markets<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Market Perform<\/td><td>US$14.00<\/td><td>US$13.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Klarna Group (KLAR) \u2014 BMO Capital Markets lowered its price target from $14.00 to $13.00, maintaining a Market Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Klarna Group<\/strong><small>KLAR<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$18.00<\/td><td>US$17.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Klarna Group (KLAR) \u2014 JPMorgan Chase &amp; Co. lowered its price target from $18.00 to $17.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Klarna Group<\/strong><small>KLAR<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$17.00<\/td><td>US$14.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Klarna Group (KLAR) \u2014 Morgan Stanley lowered its price target from $17.00 to $14.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>Lantern Pharma<\/strong><small>LTRN<\/small><\/td><td>U.S.<\/td><td>Rodman &amp; Renshaw<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Neutral<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Lantern Pharma (LTRN) \u2014 Rodman &amp; Renshaw downgraded the stock from Buy to Neutral.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Resumes\"><td><strong>Liberty Global<\/strong><small>LBTYA<\/small><\/td><td>U.S.<\/td><td>Citigroup<\/td><td><span class=\"dr-badge \">Resumes<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>\u2014<\/td><td>US$11.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Liberty Global (LBTYA) \u2014 Citigroup resumed coverage with a Neutral rating and a price target of $11.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>LifeMD<\/strong><small>LFMD<\/small><\/td><td>U.S.<\/td><td>HC Wainwright<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$9.00<\/td><td>US$6.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>LifeMD (LFMD) \u2014 HC Wainwright lowered its price target from $9.00 to $6.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Liftoff Mobile<\/strong><small>LFTO<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$25.00<\/td><td>US$35.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Liftoff Mobile (LFTO) \u2014 UBS Group raised its price target from $25.00 to $35.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Lodestar Metals Corp.<\/strong><small>LSTR:CA<\/small><\/td><td>Canada<\/td><td>Fundamental Research<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>C$0.33<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Lodestar Metals Corp. (LSTR:CA) \u2014 Fundamental Research maintained a Buy rating with a price target of C$0.33.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Lowe&#039;s Companies<\/strong><small>LOW<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Hold<\/td><td>\u2014<\/td><td>US$235.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Lowe&#039;s Companies (LOW) \u2014 TD Cowen reiterated its Hold rating with a price target of $235.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Lowe&#039;s Companies<\/strong><small>LOW<\/small><\/td><td>U.S.<\/td><td>Truist Financial<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$254.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Lowe&#039;s Companies (LOW) \u2014 Truist Financial reiterated its price target with a price target of $254.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Lumexa Imaging<\/strong><small>LMRI<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$19.00<\/td><td>US$21.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Lumexa Imaging (LMRI) \u2014 Wells Fargo &amp; Company raised its price target from $19.00 to $21.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>LuxExperience B.V.<\/strong><small>LUXE<\/small><\/td><td>U.S.<\/td><td>B. Riley Financial<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$13.00<\/td><td>US$14.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>LuxExperience B.V. (LUXE) \u2014 B. Riley Financial reiterated its Buy rating with its price target from $13.00 to $14.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>LuxExperience B.V.<\/strong><small>LUXE<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$12.00<\/td><td>US$13.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>LuxExperience B.V. (LUXE) \u2014 TD Cowen raised its price target from $12.00 to $13.50, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Manhattan Associates<\/strong><small>MANH<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>\u2014<\/td><td>US$308.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Manhattan Associates (MANH) \u2014 JPMorgan Chase &amp; Co. initiated coverage with a Overweight rating and a price target of $308.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>MARA Holdings<\/strong><small>MARA<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$27.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>MARA Holdings (MARA) \u2014 BTIG Research reiterated its Buy rating with a price target of $27.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Matador Resources<\/strong><small>MTDR<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$69.00<\/td><td>US$70.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Matador Resources (MTDR) \u2014 Morgan Stanley raised its price target from $69.00 to $70.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>McDonald&#039;s<\/strong><small>MCD<\/small><\/td><td>U.S.<\/td><td>KeyCorp<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>McDonald&#039;s (MCD) \u2014 KeyCorp reiterated its Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>McKesson<\/strong><small>MCK<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$1,000.00<\/td><td>US$1,235.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>McKesson (MCK) \u2014 Barclays raised its price target from $1,000.00 to $1,235.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>MDU Resources Group<\/strong><small>MDU<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Hold<\/td><td>\u2014<\/td><td>US$22.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>MDU Resources Group (MDU) \u2014 TD Cowen reiterated its Hold rating with a price target of $22.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Metro Inc.<\/strong><small>MRU:CA<\/small><\/td><td>Canada<\/td><td>CIBC<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>C$112.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Metro Inc. (MRU:CA) \u2014 CIBC maintained an Outperform rating with a price target of C$112.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Metro Inc.<\/strong><small>MRU:CA<\/small><\/td><td>Canada<\/td><td>TD Securities<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>C$108.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Metro Inc. (MRU:CA) \u2014 TD Securities maintained a Buy rating with a price target of C$108.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Micron Technology<\/strong><small>MU<\/small><\/td><td>U.S.<\/td><td>Royal Bank Of Canada<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>US$1,500.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Micron Technology (MU) \u2014 Royal Bank Of Canada reiterated its Outperform rating with a price target of $1,500.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Microsoft<\/strong><small>MSFT<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$625.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Microsoft (MSFT) \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $625.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Microsoft<\/strong><small>MSFT<\/small><\/td><td>U.S.<\/td><td>Mizuho<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$625.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Microsoft (MSFT) \u2014 Mizuho reiterated its price target with a price target of $625.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Microsoft<\/strong><small>MSFT<\/small><\/td><td>U.S.<\/td><td>Oppenheimer<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Microsoft (MSFT) \u2014 Oppenheimer reiterated its Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Microsoft<\/strong><small>MSFT<\/small><\/td><td>U.S.<\/td><td>Piper Sandler<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Microsoft (MSFT) \u2014 Piper Sandler reiterated its Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Microsoft<\/strong><small>MSFT<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$650.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Microsoft (MSFT) \u2014 TD Cowen reiterated its Buy rating with a price target of $650.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Microsoft<\/strong><small>MSFT<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Microsoft (MSFT) \u2014 UBS Group reiterated its Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Middleby<\/strong><small>MIDD<\/small><\/td><td>U.S.<\/td><td>Oppenheimer<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Middleby (MIDD) \u2014 Oppenheimer reiterated its Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Midera Food Processing<\/strong><small>MFP<\/small><\/td><td>U.S.<\/td><td>Robert W. Baird<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$40.00<\/td><td>US$43.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Midera Food Processing (MFP) \u2014 Robert W. Baird raised its price target from $40.00 to $43.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>Millicom International Cellular<\/strong><small>TIGO<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Neutral<\/td><td>Overweight<\/td><td>\u2014<\/td><td>US$105.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Millicom International Cellular (TIGO) \u2014 JPMorgan Chase &amp; Co. upgraded the stock from Neutral to Overweight, with a price target of $105.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Molson Coors Beverage<\/strong><small>TAP<\/small><\/td><td>U.S.<\/td><td>Wolfe Research<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Molson Coors Beverage (TAP) \u2014 Wolfe Research initiated coverage with a Peer Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Monster Beverage<\/strong><small>MNST<\/small><\/td><td>U.S.<\/td><td>Wolfe Research<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Monster Beverage (MNST) \u2014 Wolfe Research initiated coverage with a Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Resumes\"><td><strong>MP Materials<\/strong><small>MP<\/small><\/td><td>U.S.<\/td><td>Needham<\/td><td><span class=\"dr-badge \">Resumes<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$48.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>MP Materials (MP) \u2014 Needham resumed coverage with a Buy rating and a price target of $48.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>MP Materials<\/strong><small>MP<\/small><\/td><td>U.S.<\/td><td>Needham &amp; Company LLC<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$48.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>MP Materials (MP) \u2014 Needham &amp; Company LLC initiated coverage with a Buy rating and a price target of $48.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Murphy Oil<\/strong><small>MUR<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Underweight<\/td><td>US$37.00<\/td><td>US$39.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Murphy Oil (MUR) \u2014 Morgan Stanley raised its price target from $37.00 to $39.00, maintaining an Underweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade|Target Down\"><td><strong>New York Times<\/strong><small>NYT<\/small><\/td><td>U.S.<\/td><td>Citigroup<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Neutral<\/td><td>US$85.00<\/td><td>US$76.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>New York Times (NYT) \u2014 Citigroup downgraded the stock from Buy to Neutral and changed its price target from $85.00 to $76.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>NIKE<\/strong><small>NKE<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$45.00<\/td><td>US$42.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NIKE (NKE) \u2014 Barclays lowered its price target from $45.00 to $42.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NIKE<\/strong><small>NKE<\/small><\/td><td>U.S.<\/td><td>BMO Capital Markets<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Underperform<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NIKE (NKE) \u2014 BMO Capital Markets reiterated its Underperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NIKE<\/strong><small>NKE<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NIKE (NKE) \u2014 BTIG Research reiterated its Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NIKE<\/strong><small>NKE<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$38.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NIKE (NKE) \u2014 JPMorgan Chase &amp; Co. reiterated its price target with a price target of $38.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NIKE<\/strong><small>NKE<\/small><\/td><td>U.S.<\/td><td>Needham &amp; Company LLC<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Hold<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NIKE (NKE) \u2014 Needham &amp; Company LLC reiterated its Hold rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Nucor<\/strong><small>NUE<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$305.00<\/td><td>US$308.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Nucor (NUE) \u2014 Wells Fargo &amp; Company raised its price target from $305.00 to $308.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Argus<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$220.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Argus reiterated its Buy rating with a price target of $220.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>BMO Capital Markets<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 BMO Capital Markets reiterated its Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Citigroup<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$225.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Citigroup reiterated its price target with a price target of $225.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>DA Davidson<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$200.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 DA Davidson reiterated its Buy rating with a price target of $200.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>HSBC<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$170.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 HSBC reiterated its price target with a price target of $170.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Jefferies Financial Group<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$300.00<\/td><td>US$250.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Jefferies Financial Group reiterated its Buy rating with its price target from $300.00 to $250.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$215.00<\/td><td>US$230.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 JPMorgan Chase &amp; Co. reiterated its Overweight rating with its price target from $215.00 to $230.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>KeyCorp<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 KeyCorp reiterated its Sector Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Melius Research<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$185.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Melius Research reiterated its price target with a price target of $185.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$267.00<\/td><td>US$260.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Morgan Stanley lowered its price target from $267.00 to $260.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Needham &amp; Company LLC<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$200.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Needham &amp; Company LLC reiterated its Buy rating with a price target of $200.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Piper Sandler<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$300.00<\/td><td>US$230.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Piper Sandler reiterated its Overweight rating with its price target from $300.00 to $230.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Royal Bank Of Canada<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>US$230.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Royal Bank Of Canada reiterated its Outperform rating with a price target of $230.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Summit Insights<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Hold<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Summit Insights downgraded the stock from Buy to Hold.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Susquehanna<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Positive<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Susquehanna reiterated its Positive rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Truist Financial<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$174.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Truist Financial reiterated its price target with a price target of $174.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Wedbush<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$275.00<\/td><td>US$293.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Wedbush raised its price target from $275.00 to $293.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>NVIDIA<\/strong><small>NVDA<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$300.00<\/td><td>US$250.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>NVIDIA (NVDA) \u2014 Wells Fargo &amp; Company lowered its price target from $300.00 to $250.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Oaktree Specialty Lending<\/strong><small>OCSL<\/small><\/td><td>U.S.<\/td><td>Keefe, Bruyette &amp; Woods<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Market Perform<\/td><td>US$13.50<\/td><td>US$12.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Oaktree Specialty Lending (OCSL) \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $13.50 to $12.50, maintaining a Market Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>OGE Energy<\/strong><small>OGE<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$53.00<\/td><td>US$56.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>OGE Energy (OGE) \u2014 JPMorgan Chase &amp; Co. raised its price target from $53.00 to $56.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Once Upon A Farm<\/strong><small>OFRM<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$13.00<\/td><td>US$14.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Once Upon A Farm (OFRM) \u2014 JPMorgan Chase &amp; Co. raised its price target from $13.00 to $14.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Oncocyte<\/strong><small>IMDX<\/small><\/td><td>U.S.<\/td><td>Stephens<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>\u2014<\/td><td>US$4.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Oncocyte (IMDX) \u2014 Stephens reiterated its Equal Weight rating with a price target of $4.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>OneWater Marine<\/strong><small>ONEW<\/small><\/td><td>U.S.<\/td><td>KeyCorp<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>OneWater Marine (ONEW) \u2014 KeyCorp reiterated its Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Opera<\/strong><small>OPRA<\/small><\/td><td>U.S.<\/td><td>B. Riley Financial<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$28.00<\/td><td>US$27.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Opera (OPRA) \u2014 B. Riley Financial lowered its price target from $28.00 to $27.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Oric Pharmaceuticals<\/strong><small>ORIC<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$25.00<\/td><td>US$23.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Oric Pharmaceuticals (ORIC) \u2014 Wells Fargo &amp; Company lowered its price target from $25.00 to $23.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>OrthoPediatrics<\/strong><small>KIDS<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$30.00<\/td><td>US$40.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>OrthoPediatrics (KIDS) \u2014 BTIG Research raised its price target from $30.00 to $40.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Ovintiv<\/strong><small>OVV<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$71.00<\/td><td>US$72.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Ovintiv (OVV) \u2014 Morgan Stanley raised its price target from $71.00 to $72.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Paysafe<\/strong><small>PSFE<\/small><\/td><td>U.S.<\/td><td>Susquehanna<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$7.00<\/td><td>US$3.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Paysafe (PSFE) \u2014 Susquehanna lowered its price target from $7.00 to $3.50, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>PepsiCo<\/strong><small>PEP<\/small><\/td><td>U.S.<\/td><td>Wolfe Research<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>PepsiCo (PEP) \u2014 Wolfe Research initiated coverage with a Peer Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Petroleo Brasileiro S.A. - Petrobras<\/strong><small>PBR<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$24.00<\/td><td>US$23.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Petroleo Brasileiro S.A. - Petrobras (PBR) \u2014 JPMorgan Chase &amp; Co. lowered its price target from $24.00 to $23.50, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Phathom Pharmaceuticals<\/strong><small>PHAT<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$14.00<\/td><td>US$10.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Phathom Pharmaceuticals (PHAT) \u2014 Barclays lowered its price target from $14.00 to $10.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Pilgrim&#039;s Pride<\/strong><small>PPC<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$28.00<\/td><td>US$31.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Pilgrim&#039;s Pride (PPC) \u2014 UBS Group raised its price target from $28.00 to $31.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Planet Fitness<\/strong><small>PLNT<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$80.00<\/td><td>US$83.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Planet Fitness (PLNT) \u2014 UBS Group raised its price target from $80.00 to $83.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Target Up\"><td><strong>PMET Resources Inc.<\/strong><small>PMET:CA<\/small><\/td><td>Canada<\/td><td>National Bank<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>C$7.75<\/td><td>C$8.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>PMET Resources Inc. (PMET:CA) \u2014 National Bank raised its price target from C$7.75 to C$8.50, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Portland General Electric<\/strong><small>POR<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$50.00<\/td><td>US$48.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Portland General Electric (POR) \u2014 JPMorgan Chase &amp; Co. lowered its price target from $50.00 to $48.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Portman Ridge Finance<\/strong><small>BCIC<\/small><\/td><td>U.S.<\/td><td>Keefe, Bruyette &amp; Woods<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Market Perform<\/td><td>US$7.50<\/td><td>US$6.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Portman Ridge Finance (BCIC) \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $7.50 to $6.50, maintaining a Market Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Prelude Therapeutics<\/strong><small>PRLD<\/small><\/td><td>U.S.<\/td><td>HC Wainwright<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$8.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Prelude Therapeutics (PRLD) \u2014 HC Wainwright reiterated its Buy rating with a price target of $8.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Procter &amp; Gamble<\/strong><small>PG<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$180.00<\/td><td>US$188.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Procter &amp; Gamble (PG) \u2014 Wells Fargo &amp; Company raised its price target from $180.00 to $188.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Pulmonx<\/strong><small>LUNG<\/small><\/td><td>U.S.<\/td><td>Loop Capital<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td>US$7.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Pulmonx (LUNG) \u2014 Loop Capital reiterated its price target with a price target of $7.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Qualcomm<\/strong><small>QCOM<\/small><\/td><td>U.S.<\/td><td>Robert W. Baird<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$320.00<\/td><td>US$300.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Qualcomm (QCOM) \u2014 Robert W. Baird lowered its price target from $320.00 to $300.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Range Resources<\/strong><small>RRC<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$45.00<\/td><td>US$50.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Range Resources (RRC) \u2014 Morgan Stanley raised its price target from $45.00 to $50.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Recursion Pharmaceuticals<\/strong><small>RXRX<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$5.90<\/td><td>US$5.60<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Recursion Pharmaceuticals (RXRX) \u2014 Morgan Stanley lowered its price target from $5.90 to $5.60, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Rein Therapeutics<\/strong><small>RNTX<\/small><\/td><td>U.S.<\/td><td>HC Wainwright<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Rein Therapeutics (RNTX) \u2014 HC Wainwright reiterated its Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Reliance<\/strong><small>RS<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$420.00<\/td><td>US$452.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Reliance (RS) \u2014 Wells Fargo &amp; Company raised its price target from $420.00 to $452.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Relx<\/strong><small>RELX<\/small><\/td><td>U.S.<\/td><td>Erste Group Bank<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Relx (RELX) \u2014 Erste Group Bank initiated coverage with a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Royalty Pharma<\/strong><small>RPRX<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$68.00<\/td><td>US$80.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Royalty Pharma (RPRX) \u2014 TD Cowen raised its price target from $68.00 to $80.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Sabre<\/strong><small>SABR<\/small><\/td><td>U.S.<\/td><td>Cantor Fitzgerald<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>\u2014<\/td><td>US$2.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Sabre (SABR) \u2014 Cantor Fitzgerald reiterated its Neutral rating with a price target of $2.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Salesforce<\/strong><small>CRM<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$300.00<\/td><td>US$250.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Salesforce (CRM) \u2014 BTIG Research lowered its price target from $300.00 to $250.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Savaria Corp.<\/strong><small>SIS:CA<\/small><\/td><td>Canada<\/td><td>TD Securities<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>C$38.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Savaria Corp. (SIS:CA) \u2014 TD Securities maintained a Buy rating with a price target of C$38.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Securitize<\/strong><small>SECZ<\/small><\/td><td>U.S.<\/td><td>B. Riley Financial<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$14.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Securitize (SECZ) \u2014 B. Riley Financial initiated coverage with a Buy rating and a price target of $14.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Securitize<\/strong><small>SECZ<\/small><\/td><td>U.S.<\/td><td>B. Riley Securities<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$14.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Securitize (SECZ) \u2014 B. Riley Securities initiated coverage with a Buy rating and a price target of $14.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>ServiceTitan<\/strong><small>TTAN<\/small><\/td><td>U.S.<\/td><td>Piper Sandler<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>\u2014<\/td><td>US$110.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>ServiceTitan (TTAN) \u2014 Piper Sandler reiterated its Overweight rating with a price target of $110.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Sherwin-Williams<\/strong><small>SHW<\/small><\/td><td>U.S.<\/td><td>Argus<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$380.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Sherwin-Williams (SHW) \u2014 Argus reiterated its Buy rating with a price target of $380.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Sienna Senior Living Inc.<\/strong><small>SIA:CA<\/small><\/td><td>Canada<\/td><td>Scotiabank<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Sector Outperform<\/td><td>\u2014<\/td><td>C$26.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Sienna Senior Living Inc. (SIA:CA) \u2014 Scotiabank maintained a Sector Outperform rating with a price target of C$26.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Similarweb<\/strong><small>SMWB<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$11.00<\/td><td>US$13.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Similarweb (SMWB) \u2014 Barclays raised its price target from $11.00 to $13.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Sinclair<\/strong><small>SBGI<\/small><\/td><td>U.S.<\/td><td>Guggenheim<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$19.00<\/td><td>US$20.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Sinclair (SBGI) \u2014 Guggenheim raised its price target from $19.00 to $20.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>SKYX Platforms<\/strong><small>SKYX<\/small><\/td><td>U.S.<\/td><td>Subscribe to MarketBeat All Access to unlock brokerage rankings<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$2.50<\/td><td>US$2.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>SKYX Platforms (SKYX) \u2014 Subscribe to MarketBeat All Access to unlock brokerage rankings lowered its price target from $2.50 to $2.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>SLR Investment<\/strong><small>SLRC<\/small><\/td><td>U.S.<\/td><td>Keefe, Bruyette &amp; Woods<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Market Perform<\/td><td>US$13.50<\/td><td>US$13.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>SLR Investment (SLRC) \u2014 Keefe, Bruyette &amp; Woods lowered its price target from $13.50 to $13.00, maintaining a Market Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Snowflake<\/strong><small>SNOW<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$500.00<\/td><td>US$450.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Snowflake (SNOW) \u2014 UBS Group lowered its price target from $500.00 to $450.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Snowline Gold Corp.<\/strong><small>SGD:CA<\/small><\/td><td>Canada<\/td><td>CIBC<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>C$27.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Snowline Gold Corp. (SGD:CA) \u2014 CIBC maintained an Outperform rating with a price target of C$27.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>SOLV Energy<\/strong><small>MWH<\/small><\/td><td>U.S.<\/td><td>UBS<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Neutral<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$37.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>SOLV Energy (MWH) \u2014 UBS upgraded the stock from Neutral to Buy, with a price target of $37.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade|Target Down\"><td><strong>SOLV Energy<\/strong><small>MWH<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Neutral<\/td><td>Buy<\/td><td>US$50.00<\/td><td>US$37.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>SOLV Energy (MWH) \u2014 UBS Group upgraded the stock from Neutral to Buy and changed its price target from $50.00 to $37.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Spire<\/strong><small>SR<\/small><\/td><td>U.S.<\/td><td>Mizuho<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$93.00<\/td><td>US$96.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Spire (SR) \u2014 Mizuho raised its price target from $93.00 to $96.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Steel Dynamics<\/strong><small>STLD<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$271.00<\/td><td>US$285.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Steel Dynamics (STLD) \u2014 Wells Fargo &amp; Company raised its price target from $271.00 to $285.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Stryker<\/strong><small>SYK<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$304.00<\/td><td>US$345.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Stryker (SYK) \u2014 BTIG Research raised its price target from $304.00 to $345.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>Summit Therapeutics<\/strong><small>SMMT<\/small><\/td><td>U.S.<\/td><td>Bernstein<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Market Perform<\/td><td>Underperform<\/td><td>\u2014<\/td><td>US$8.30<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Summit Therapeutics (SMMT) \u2014 Bernstein downgraded the stock from Market Perform to Underperform, with a price target of $8.30.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade|Target Down\"><td><strong>Summit Therapeutics<\/strong><small>SMMT<\/small><\/td><td>U.S.<\/td><td>Sanford C. Bernstein<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Market Perform<\/td><td>Underperform<\/td><td>US$11.90<\/td><td>US$8.30<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Summit Therapeutics (SMMT) \u2014 Sanford C. Bernstein downgraded the stock from Market Perform to Underperform and changed its price target from $11.90 to $8.30.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Target Down\"><td><strong>Superior Plus Corp.<\/strong><small>SPB:CA<\/small><\/td><td>Canada<\/td><td>Stifel Nicolaus<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>C$10.00<\/td><td>C$8.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Superior Plus Corp. (SPB:CA) \u2014 Stifel Nicolaus lowered its price target from C$10.00 to C$8.50, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Tandem Diabetes Care<\/strong><small>TNDM<\/small><\/td><td>U.S.<\/td><td>Lake Street Capital<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Tandem Diabetes Care (TNDM) \u2014 Lake Street Capital initiated coverage with a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Tandem Diabetes Care<\/strong><small>TNDM<\/small><\/td><td>U.S.<\/td><td>Piper Sandler<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Tandem Diabetes Care (TNDM) \u2014 Piper Sandler initiated coverage with a Neutral ? Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>Tandem Diabetes Care<\/strong><small>TNDM<\/small><\/td><td>U.S.<\/td><td>Raymond James Financial<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Market Perform<\/td><td>Strong-Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Tandem Diabetes Care (TNDM) \u2014 Raymond James Financial upgraded the stock from Market Perform to Strong-Buy.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade|Target Up\"><td><strong>Tandem Diabetes Care<\/strong><small>TNDM<\/small><\/td><td>U.S.<\/td><td>Stifel Nicolaus<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Hold<\/td><td>Buy<\/td><td>US$22.00<\/td><td>US$26.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Tandem Diabetes Care (TNDM) \u2014 Stifel Nicolaus upgraded the stock from Hold to Buy and changed its price target from $22.00 to $26.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Upgrade\"><td><strong>Tandem Diabetes Care<\/strong><small>TNDM<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge dr-up\">Upgrade<\/span><\/td><td>Neutral<\/td><td>Buy<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Tandem Diabetes Care (TNDM) \u2014 UBS Group upgraded the stock from Neutral to Buy.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Tencent Music Entertainment Group<\/strong><small>TME<\/small><\/td><td>U.S.<\/td><td>Mizuho<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>US$15.00<\/td><td>US$14.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Tencent Music Entertainment Group (TME) \u2014 Mizuho lowered its price target from $15.00 to $14.00, maintaining an Outperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Target Down\"><td><strong>Transat A.T. Inc.<\/strong><small>TRZ:CA<\/small><\/td><td>Canada<\/td><td>CIBC<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Underperform<\/td><td>C$1.75<\/td><td>C$1.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Transat A.T. Inc. (TRZ:CA) \u2014 CIBC lowered its price target from C$1.75 to C$1.50, maintaining an Underperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Target Down\"><td><strong>Transat A.T. Inc.<\/strong><small>TRZ:CA<\/small><\/td><td>Canada<\/td><td>National Bank<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Underperform<\/td><td>C$1.50<\/td><td>C$1.15<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Transat A.T. Inc. (TRZ:CA) \u2014 National Bank lowered its price target from C$1.50 to C$1.15, maintaining an Underperform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Tyler Technologies<\/strong><small>TYL<\/small><\/td><td>U.S.<\/td><td>TD Cowen<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$450.00<\/td><td>US$475.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Tyler Technologies (TYL) \u2014 TD Cowen raised its price target from $450.00 to $475.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Tyler Technologies<\/strong><small>TYL<\/small><\/td><td>U.S.<\/td><td>Truist Financial<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$440.00<\/td><td>US$500.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Tyler Technologies (TYL) \u2014 Truist Financial reiterated its Buy rating with its price target from $440.00 to $500.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Tyson Foods<\/strong><small>TSN<\/small><\/td><td>U.S.<\/td><td>Bank of America<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>US$56.00<\/td><td>US$65.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Tyson Foods (TSN) \u2014 Bank of America raised its price target from $56.00 to $65.00, maintaining a Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>uniQure<\/strong><small>QURE<\/small><\/td><td>U.S.<\/td><td>HC Wainwright<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$80.00<\/td><td>US$65.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>uniQure (QURE) \u2014 HC Wainwright lowered its price target from $80.00 to $65.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>United States Antimony<\/strong><small>UAMY<\/small><\/td><td>U.S.<\/td><td>B. Riley Financial<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$10.00<\/td><td>US$6.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>United States Antimony (UAMY) \u2014 B. Riley Financial lowered its price target from $10.00 to $6.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Vericel<\/strong><small>VCEL<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Neutral<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Vericel (VCEL) \u2014 BTIG Research reiterated its Neutral rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Initiates\"><td><strong>Veritone<\/strong><small>VERI<\/small><\/td><td>U.S.<\/td><td>HC Wainwright<\/td><td><span class=\"dr-badge \">Initiates<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$2.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Veritone (VERI) \u2014 HC Wainwright initiated coverage with a Buy rating and a price target of $2.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Viking<\/strong><small>VIK<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$102.00<\/td><td>US$111.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Viking (VIK) \u2014 Barclays raised its price target from $102.00 to $111.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Viking<\/strong><small>VIK<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$131.00<\/td><td>US$122.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Viking (VIK) \u2014 JPMorgan Chase &amp; Co. lowered its price target from $131.00 to $122.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Viking<\/strong><small>VIK<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$92.00<\/td><td>US$100.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Viking (VIK) \u2014 Morgan Stanley raised its price target from $92.00 to $100.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Viking<\/strong><small>VIK<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$118.00<\/td><td>US$120.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Viking (VIK) \u2014 Wells Fargo &amp; Company raised its price target from $118.00 to $120.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Vista Energy<\/strong><small>VIST<\/small><\/td><td>U.S.<\/td><td>UBS Group<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$80.00<\/td><td>US$100.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Vista Energy (VIST) \u2014 UBS Group raised its price target from $80.00 to $100.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Target Down\"><td><strong>Vital Infrastructure Property Trust<\/strong><small>VITL.UN:CA<\/small><\/td><td>Canada<\/td><td>RBC<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Sector Perform<\/td><td>C$6.00<\/td><td>C$5.50<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Vital Infrastructure Property Trust (VITL.UN:CA) \u2014 RBC lowered its price target from C$6.00 to C$5.50, maintaining a Sector Perform rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Downgrade\"><td><strong>VolitionRx<\/strong><small>VNRX<\/small><\/td><td>U.S.<\/td><td>Freedom Broker<\/td><td><span class=\"dr-badge dr-down\">Downgrade<\/span><\/td><td>Buy<\/td><td>Hold<\/td><td>\u2014<\/td><td>\u2014<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>VolitionRx (VNRX) \u2014 Freedom Broker downgraded the stock from Buy to Hold.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Walt Disney<\/strong><small>DIS<\/small><\/td><td>U.S.<\/td><td>Bank of America<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$125.00<\/td><td>US$135.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Walt Disney (DIS) \u2014 Bank of America raised its price target from $125.00 to $135.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Walt Disney<\/strong><small>DIS<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$115.00<\/td><td>US$135.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Walt Disney (DIS) \u2014 Barclays raised its price target from $115.00 to $135.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Walt Disney<\/strong><small>DIS<\/small><\/td><td>U.S.<\/td><td>Guggenheim<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$120.00<\/td><td>US$135.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Walt Disney (DIS) \u2014 Guggenheim raised its price target from $120.00 to $135.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Walt Disney<\/strong><small>DIS<\/small><\/td><td>U.S.<\/td><td>JPMorgan Chase &amp; Co.<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$137.00<\/td><td>US$140.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Walt Disney (DIS) \u2014 JPMorgan Chase &amp; Co. raised its price target from $137.00 to $140.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Walt Disney<\/strong><small>DIS<\/small><\/td><td>U.S.<\/td><td>Needham &amp; Company LLC<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$125.00<\/td><td>US$135.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Walt Disney (DIS) \u2014 Needham &amp; Company LLC raised its price target from $125.00 to $135.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Walt Disney<\/strong><small>DIS<\/small><\/td><td>U.S.<\/td><td>Raymond James Financial<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Outperform<\/td><td>\u2014<\/td><td>US$133.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Walt Disney (DIS) \u2014 Raymond James Financial reiterated its Outperform rating with a price target of $133.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Walt Disney<\/strong><small>DIS<\/small><\/td><td>U.S.<\/td><td>Rosenblatt Securities<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$126.00<\/td><td>US$141.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Walt Disney (DIS) \u2014 Rosenblatt Securities raised its price target from $126.00 to $141.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Up\"><td><strong>Walt Disney<\/strong><small>DIS<\/small><\/td><td>U.S.<\/td><td>Wells Fargo &amp; Company<\/td><td><span class=\"dr-badge \">Target Up<\/span><\/td><td>\u2014<\/td><td>Overweight<\/td><td>US$132.00<\/td><td>US$140.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Walt Disney (DIS) \u2014 Wells Fargo &amp; Company raised its price target from $132.00 to $140.00, maintaining an Overweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>XPENG<\/strong><small>XPEV<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Underweight<\/td><td>US$14.00<\/td><td>US$12.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>XPENG (XPEV) \u2014 Barclays lowered its price target from $14.00 to $12.00, maintaining an Underweight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"Canada\" data-tags=\"Maintains\"><td><strong>Xtract One Technologies Inc.<\/strong><small>XTRA:CA<\/small><\/td><td>Canada<\/td><td>Ventum Financial<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>C$1.15<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Xtract One Technologies Inc. (XTRA:CA) \u2014 Ventum Financial maintained a Buy rating with a price target of C$1.15.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>York Space Systems<\/strong><small>YSS<\/small><\/td><td>U.S.<\/td><td>Barclays<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$11.00<\/td><td>US$5.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>York Space Systems (YSS) \u2014 Barclays lowered its price target from $11.00 to $5.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>Zoom Communications<\/strong><small>ZM<\/small><\/td><td>U.S.<\/td><td>BTIG Research<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>US$125.00<\/td><td>US$115.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Zoom Communications (ZM) \u2014 BTIG Research lowered its price target from $125.00 to $115.00, maintaining a Buy rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Maintains\"><td><strong>Zoom Communications<\/strong><small>ZM<\/small><\/td><td>U.S.<\/td><td>Rosenblatt Securities<\/td><td><span class=\"dr-badge \">Maintains<\/span><\/td><td>\u2014<\/td><td>Buy<\/td><td>\u2014<\/td><td>US$130.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>Zoom Communications (ZM) \u2014 Rosenblatt Securities reiterated its Buy rating with a price target of $130.00.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<tr data-dr-row data-market=\"U.S.\" data-tags=\"Target Down\"><td><strong>ZoomInfo Technologies<\/strong><small>GTM<\/small><\/td><td>U.S.<\/td><td>Morgan Stanley<\/td><td><span class=\"dr-badge \">Target Down<\/span><\/td><td>\u2014<\/td><td>Equal Weight<\/td><td>US$5.00<\/td><td>US$4.00<\/td><td><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">Report<\/a><details><summary>Details<\/summary><p>ZoomInfo Technologies (GTM) \u2014 Morgan Stanley lowered its price target from $5.00 to $4.00, maintaining an Equal Weight rating.<\/p><small>Report title<\/small><\/details><\/td><\/tr>\n<\/tbody><\/table><\/div>\n<p id=\"dr-empty\" hidden>No matching calls. Try another date, market or search.<\/p>\n<p class=\"dr-note\">Report date: 2026-11-18 \u00b7 Dates use America\/New_York. Automatically reflects published daily analyst reports. Coverage is limited to recognizable entries in those reports; missing fields appear as \u2014. Targets retain the currency stated in the report. Exact duplicate calls are removed; different analysts and materially different updates remain separate. Summary counts cover the selected date before filtering.<\/p>\n<section class=\"dr-sources\"><h3>Source reports for this date<\/h3><p><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-18-2026\/\">American Analyst Ratings Updates \u2014 November 18, 2026<\/a><\/p><p><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canadian-analyst-ratings-updates-november-18-2026\/\">Canadian Analyst Ratings Updates \u2014 November 18, 2026<\/a><\/p><p class=\"dr-note\">Available date history comes from the latest 300 matching analyst articles. Analyst ratings and targets are estimates, not guaranteed outcomes.<\/p><\/section>\n<script>(function(){var root=document.getElementById('sta-daily-ratings');if(!root)return;var search=root.querySelector('#dr-search'),market=root.querySelector('#dr-market'),action=root.querySelector('#dr-action'),rows=Array.from(root.querySelectorAll('[data-dr-row]'));function filter(){var q=search.value.trim().toLowerCase(),n=0;rows.forEach(function(row){var show=(!q||row.textContent.toLowerCase().indexOf(q)!==-1)&&(!market.value||row.dataset.market===market.value)&&(!action.value||row.dataset.tags.split('|').indexOf(action.value)!==-1);row.hidden=!show;if(show)n++;});root.querySelector('#dr-count').textContent=n+' of '+rows.length+' calls shown';root.querySelector('#dr-empty').hidden=n>0;}search.addEventListener('input',filter);market.addEventListener('change',filter);action.addEventListener('change',filter);})();<\/script>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>Explore our research toolsTarget Tool &rarr;Analyst Ranking Tool &rarr;<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-77195","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Daily Analyst Ratings | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daily Analyst Ratings\" \/>\n<meta property=\"og:description\" content=\"Explore our research toolsTarget Tool &rarr;Analyst Ranking Tool &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-19T05:55:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2019\/11\/Stock-Target-Advisor.png\" \/>\n\t<meta property=\"og:image:width\" content=\"291\" \/>\n\t<meta property=\"og:image:height\" content=\"59\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/\",\"name\":\"Daily Analyst Ratings | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-11-18T18:15:35+00:00\",\"dateModified\":\"2026-11-19T05:55:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daily Analyst Ratings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daily Analyst Ratings | Stock Target Advisor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Daily Analyst Ratings","og_description":"Explore our research toolsTarget Tool &rarr;Analyst Ranking Tool &rarr;","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_modified_time":"2026-11-19T05:55:55+00:00","og_image":[{"width":291,"height":59,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2019\/11\/Stock-Target-Advisor.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@AdvisorTarget","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/","name":"Daily Analyst Ratings | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-11-18T18:15:35+00:00","dateModified":"2026-11-19T05:55:55+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/daily-analyst-ratings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Daily Analyst Ratings"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/pages\/77195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=77195"}],"version-history":[{"count":2,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/pages\/77195\/revisions"}],"predecessor-version":[{"id":77228,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/pages\/77195\/revisions\/77228"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=77195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}